Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas

Despite significant progress in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), the prognosis of patients with relapsed disease remains poor due to the emergence of drug resistance and subsequent disease progression. Identification of novel target...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jing, Wang, Michelle Y., Ren, Yuan, Lwin, Tint, Li, Tao, Yan, Joy C., Sotomayor, Eduardo M., Duckett, Derek R., Shah, Bijal D., Shain, Kenneth H., Zhao, Xiaohong, Tao, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052927/
https://www.ncbi.nlm.nih.gov/pubmed/34162179
http://dx.doi.org/10.3324/haematol.2021.278743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052927/
https://www.ncbi.nlm.nih.gov/pubmed/34162179
http://dx.doi.org/10.3324/haematol.2021.278743

Ejemplares similares